Haematologica (Sep 2024)
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting
- Gaia Ciolli,
- Matteo Piccini,
- Francesco Mannelli,
- Giacomo Gianfaldoni,
- Barbara Scappini,
- Laura Fasano,
- Francesca Crupi,
- Elisa Quinti,
- Andrea Pasquini,
- Jessica Caroprese,
- Giada Rotunno,
- Fabiana Pancani,
- Leonardo Signori,
- Chiara Maccari,
- Fiorenza I. Vanderwert,
- Paola Guglielmelli,
- Alessandro M. Vannucchi
Affiliations
- Gaia Ciolli
- Hematology Department, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence
- Matteo Piccini
- Hematology Department, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence
- Francesco Mannelli
- Hematology Department, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy; Center for Innovation and Research in Myeloproliferative Neoplasms, Hematology Unit, Azienda Ospedaliera Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence
- Giacomo Gianfaldoni
- Hematology Department, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence
- Barbara Scappini
- Hematology Department, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence
- Laura Fasano
- Hematology Department, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence
- Francesca Crupi
- Hematology Department, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence
- Elisa Quinti
- Hematology Department, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence
- Andrea Pasquini
- Hematology Department, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence
- Jessica Caroprese
- Hematology Department, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence
- Giada Rotunno
- Center for Innovation and Research in Myeloproliferative Neoplasms, Hematology Unit, Azienda Ospedaliera Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence
- Fabiana Pancani
- Center for Innovation and Research in Myeloproliferative Neoplasms, Hematology Unit, Azienda Ospedaliera Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence
- Leonardo Signori
- Center for Innovation and Research in Myeloproliferative Neoplasms, Hematology Unit, Azienda Ospedaliera Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence
- Chiara Maccari
- Center for Innovation and Research in Myeloproliferative Neoplasms, Hematology Unit, Azienda Ospedaliera Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence
- Fiorenza I. Vanderwert
- Center for Innovation and Research in Myeloproliferative Neoplasms, Hematology Unit, Azienda Ospedaliera Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence
- Paola Guglielmelli
- Hematology Department, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy; Center for Innovation and Research in Myeloproliferative Neoplasms, Hematology Unit, Azienda Ospedaliera Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence
- Alessandro M. Vannucchi
- Hematology Department, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy; Center for Innovation and Research in Myeloproliferative Neoplasms, Hematology Unit, Azienda Ospedaliera Universitaria Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence
- DOI
- https://doi.org/10.3324/haematol.2024.285934
- Journal volume & issue
-
Vol. 999,
no. 1
Abstract
Not available.
